Page 1329 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

experience in 126 treated patients. Ann Intern Med. April 1, and management. Leuk Lymphoma. September 2000;39(1-2):
1990;112(7):499-504. 1-18.
98. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide 115. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM.
for hypercalcemia: an unproven yet common practice. Ann Hyperleukocytosis, leukostasis and leukapheresis: practice
Intern Med. August 19, 2008;149(4):259-263. management. Blood Rev. May 2012;26(3):117-122.
99. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior 116. Majhail NS, Lichtin AE. Acute leukemia with a very high leuko-
to pamidronate in the treatment of hypercalcemia of malig- cyte count: confronting a medical emergency. Cleve Clin J Med.
nancy: a pooled analysis of two randomized, controlled clinical August 2004;71(8):633-637.
trials. J Clin Oncol. January 15, 2001;19(2):558-567. 117. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal S,
100. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines Kribben A, Duhrsen U. Grading of symptoms in hyperleuko-
for the management of pediatric and adult tumor lysis syn- cytic leukaemia: a clinical model for the role of different blast
drome: an evidence-based review. J Clin Oncol. June 1, 2008; types and promyelocytes in the development of leukostasis
26(16):2767-2778. syndrome. Eur J Haematol. June 2005;74(6):501-510.
101. Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated 118. Piccirillo N, Laurenti L, Chiusolo P, et al. Reliability of leukosta-
clinical approach for the identification, prevention, and treatment sis grading score to identify patients with high-risk hyperleuko-
of tumor lysis syndrome. Cancer Treat Rev. April 2010;36(2): cytosis. Am J Hematol. June 2009;84(6):381-382.
164-176. 119. Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG,
102. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergen- McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic
cies: pathophysiology, presentation, diagnosis, and treatment. leukaemias: lack of correlation between degree of cytoreduc-
CA Cancer J Clin. 2011;61:287-314. tion and early mortality rate. Br J Haematol. August 1997;98(2):
103. Behl D, Hendrickson AW, Moynihan TJ. Oncologic emergen- 433-436.
cies. Crit Care Clin. January 2010;26(1):181-205. 120. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice.
104. Cairo MS, Bishop M. Tumour lysis syndrome: new thera- Superior vena cava syndrome with malignant causes. N Engl J
peutic strategies and classification. Br J Haematol. October Med. May 3, 2007;356(18):1862-1869.
2004;127(1):3-11. 121. Rizvi AZ, Kalra M, Bjarnason H, Bower TC, Schleck C, Gloviczki
105. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst P. Benign superior vena cava syndrome: stenting is now the first
MM. Alkalinization and the tumor lysis syndrome. Med Pediatr line of treatment. J Vasc Surg. February 2008;47(2):372-380.
Oncol. July 1998;31(1):27-28. 122. Lepper PM, Ott SR, Hoppe H, et al. Superior vena cava syndrome
106. Brochard L, Abroug F, Brenner M, et al. An Official ATS/ERS/ in thoracic malignancies. Respir Care. May 2011;56(5):653-666.
ESICM/SCCM/SRLF Statement: Prevention and Management 123. Wan JF, Bezjak A. Superior vena cava syndrome. Hematol Oncol
of Acute Renal Failure in the ICU Patient: an international Clin North Am. June 2010;24(3):501-513.
consensus conference in intensive care medicine. Am J Respir
Crit Care Med. May 15, 2010;181(10):1128-1155. 124. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena
107. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on caval obstruction. Is it a medical emergency? Am J Med. June
1981;70(6):1169-1174.
the management of tumor lysis syndrome. Haematologica.
December 2008;93(12):1877-1885. 125. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome—
108. Pession A, Masetti R, Gaidano G, et al. Risk evaluation, prophy- a proposed classification system and algorithm for manage-
ment. J Thorac Oncol. August 2008;3(8):811-814.
laxis, and treatment of tumor lysis syndrome: consensus of an
Italian expert panel. Adv Ther. August 2011;28(8):684-697. 126. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy
109. DeConti RC, Calabresi P. Use of allopurinol for prevention and and stents for superior vena caval obstruction in carcinoma of
the bronchus. Cochrane Database Syst Rev. 2001;4:CD001316.
control of hyperuricemia in patients with neoplastic disease.
N Engl J Med. March 3, 1966;274(9):481-486. 127. Adelstein DJ, Hines JD, Carter SG, Sacco D. Thromboembolic
110. Goldman SC. Rasburicase: potential role in managing tumor events in patients with malignant superior vena cava syn-
lysis in patients with hematological malignancies. Expert Rev drome and the role of anticoagulation. Cancer. November 15,
Anticancer Ther. August 2003;3(4):429-433. 1988;62(10):2258-2262.
111. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasbu- 128. Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A.
ricase, a recombinant urate oxidase (Elitek), in the management Thromboembolic disease involving the superior vena cava and
of malignancy-associated hyperuricemia in pediatric and adult brachiocephalic veins. Chest. March 2003;123(3):809-812.
patients: final results of a multicenter compassionate use trial. 129. Nguyen NP, Borok TL, Welsh J, Vinh-Hung V. Safety and effec-
Leukemia. January 2005;19(1):34-38. tiveness of vascular endoprosthesis for malignant superior vena
112. Vines AN, Shanholtz CB, Thompson JL. Fixed-dose rasburicase cava syndrome. Thorax. February 2009;64(2):174-178.
6 mg for hyperuricemia and tumor lysis syndrome in high- 130. Lanciego C, Chacon JL, Julian A, et al. Stenting as first
risk cancer patients. Ann Pharmacother. October 2010;44(10): option for endovascular treatment of malignant superior vena
1529-1537. cava syndrome. AJR Am J Roentgenol. September 2001;177(3):
113. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis 585-593.
and hyperviscosity syndrome. Semin Thromb Hemost. June 2007; 131. Spodick DH. Acute cardiac tamponade. N Engl J Med.
33(4):350-354. August 14, 2003;349(7):684-690.
114. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and 132. Dequanter D, Lothaire P, Berghmans T, Sculier JP. Severe
leukostasis: a review of pathophysiology, clinical presentation pericardial effusion in patients with concurrent malignancy: a

Section07-O-ref.indd 4 1/21/2015 11:26:51 AM